IOVA

7.38

2.22% 0.16

Dopo l'orario di chiusura: 7.48 0.10 +1.36%

Iovance Biotherapeutics Inc (IOVA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché IOVA Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$7.22

Aprire:

$7.17

Volume 24 ore:

9.57M

Relative Volume:

1.64

Capitalizzazione di mercato:

$2.25B

Reddito:

$32.77M

Utile/perdita netta:

$-440.22M

Rapporto P/E:

-3.2946

EPS:

-2.24

Flusso di cassa netto:

$-400.48M

1 W Prestazione:

-5.75%

1M Prestazione:

-9.34%

6M Prestazione:

-7.40%

1 anno Prestazione:

+2.79%

Intervallo 1D:

$7.07

$7.44

Intervallo di 1 settimana:

$7.0602

$8.14

Portata 52W:

$6.70

$18.33

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Nome

Iovance Biotherapeutics Inc

Settore

Healthcare (1176)

Industria

Biotechnology (673)

Telefono

(650) 260-7120

Indirizzo

825 INDUSTRIAL ROAD, SAN CARLOS

Dipendente

557

Cinguettio

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

IOVA's Discussions on Twitter

Confronta IOVA con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
IOVA Iovance Biotherapeutics Inc	7.38	2.25B	32.77M	-440.22M	-400.48M	-1.67
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-10-24	Iniziato	UBS	Buy
2024-07-29	Downgrade	Piper Sandler	Overweight → Neutral
2023-11-20	Iniziato	Goldman	Buy
2023-09-18	Reiterato	Barclays	Overweight
2023-05-30	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-03-27	Ripresa	Wells Fargo	Equal Weight
2023-01-27	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-12-09	Downgrade	Goldman	Buy → Neutral
2022-10-31	Iniziato	Guggenheim	Neutral
2022-08-18	Ripresa	Wells Fargo	Equal Weight
2022-01-28	Aggiornamento	Stifel	Hold → Buy
2021-12-07	Ripresa	Cowen	Outperform
2021-06-10	Aggiornamento	JMP Securities	Mkt Perform → Mkt Outperform
2021-05-20	Downgrade	Piper Sandler	Overweight → Neutral
2021-05-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2021-05-19	Downgrade	Stifel	Buy → Hold
2021-05-03	Iniziato	Truist	Buy
2021-04-16	Iniziato	Goldman	Buy
2021-03-08	Aggiornamento	H.C. Wainwright	Neutral → Buy
2020-12-15	Downgrade	H.C. Wainwright	Buy → Neutral
2020-10-06	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-04-22	Iniziato	Mizuho	Buy
2020-03-04	Iniziato	Barclays	Overweight
2020-02-26	Reiterato	H.C. Wainwright	Buy
2020-02-26	Reiterato	Oppenheimer	Outperform
2019-12-18	Iniziato	JMP Securities	Mkt Outperform
2019-10-01	Iniziato	Stifel	Buy
2019-04-29	Iniziato	Piper Jaffray	Overweight
2019-02-28	Reiterato	Chardan Capital Markets	Buy
2019-02-07	Iniziato	Robert W. Baird	Outperform
2018-12-31	Ripresa	B. Riley FBR	Buy
2018-07-06	Reiterato	Chardan Capital Markets	Buy
2018-04-10	Aggiornamento	B. Riley FBR, Inc.	Neutral → Buy
2018-03-13	Reiterato	B. Riley FBR, Inc.	Neutral
2018-02-23	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
2018-01-25	Reiterato	H.C. Wainwright	Buy
2017-11-01	Reiterato	B. Riley FBR, Inc.	Buy

Mostra tutto

Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie

04:31 AM

Barclays PLC Raises Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

04:31 AM

01:06 AM

Where are the Opportunities in (IOVA) - Stock Traders Daily

01:06 AM

Dec 20, 2024

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Dec 20, 2024

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire Inc.

Dec 20, 2024

Dec 19, 2024

Insiders' US$48.3m Investments In Red Following Iovance Biotherapeutics' US$402m Dip In Market Value - Simply Wall St

Dec 19, 2024

Dec 17, 2024

KEI Comments on NIH Exclusive License to Iovance for T-cell Vaccine for Cancer Treatment - Knowledge Ecology International

Dec 17, 2024

Dec 16, 2024

Iovance Biotherapeutics: Amtagvi Launch Growing, But Stock Isn't (NASDAQ:IOVA) - Seeking Alpha

Dec 16, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Sees Significant Increase in Short Interest - MarketBeat

Dec 16, 2024

Dec 15, 2024

State Street Corp Grows Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Dec 15, 2024

Dec 13, 2024

Iovance Biotherapeutics' SWOT analysis: promising TIL therapy stock faces growth hurdles - Investing.com India

Dec 13, 2024

Dec 12, 2024

Interesting IOVA Call Options For January 2025 - Nasdaq

Dec 12, 2024

Prediction: This Stock Will Beat the Market in 2025 - Yahoo Finance

Dec 12, 2024

Dec 11, 2024

BNP Paribas Financial Markets Trims Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Dec 11, 2024

Dec 09, 2024

Iovance Biotherapeutics' SWOT analysis: stock shows promise amid challenges By Investing.com - Investing.com Nigeria

Dec 09, 2024

Iovance Biotherapeutics: Steady Progress (NASDAQ:IOVA) - Seeking Alpha

Dec 09, 2024

Dec 08, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Dec 08, 2024

Dec 07, 2024

Charles Schwab Investment Management Inc. Has $17.96 Million Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Dec 07, 2024

Dec 06, 2024

Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates - MSN

Dec 06, 2024

Dec 03, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a favorite amongst institutional investors who own 63% - Yahoo Finance

Dec 03, 2024

Nov 30, 2024

Braidwell LP Has $2.05 Million Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Nov 30, 2024

Nov 29, 2024

(IOVA) On The My Stocks Page - Stock Traders Daily

Nov 29, 2024

Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect - MSN

Nov 29, 2024

Intech Investment Management LLC Makes New $920,000 Investment in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Nov 29, 2024

Nov 28, 2024

IOVAIovance Biotherapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 28, 2024

Nov 27, 2024

Is Iovance Biotherapeutics Stock a Millionaire Maker? - MSN

Nov 27, 2024

Nov 26, 2024

Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer - GlobeNewswire

Nov 26, 2024

Iovance Biotherapeutics (STU:2LB) Operating Cash Flow per S - GuruFocus.com

Nov 26, 2024

Iovance Biotherapeutics (NASDAQ:IOVA) delivers shareholders favorable 68% return over 1 year, surging 10.0% in the last week alone - Simply Wall St

Nov 26, 2024

IOVA (Iovance Biotherapeutics) Total Assets : $991.12 Mil (As of Sep. 2024) - GuruFocus.com

Nov 26, 2024

Victory Capital Management Inc. Buys 115,387 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Nov 26, 2024

Nov 25, 2024

IOVA (Iovance Biotherapeutics) Cash Flow from Financing : $389.32 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 25, 2024

Nov 24, 2024

Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back - MSN

Nov 24, 2024

Landscape Capital Management L.L.C. Takes $615,000 Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Nov 24, 2024

Eagle Asset Management Inc. Lowers Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Nov 24, 2024

Nov 23, 2024